Fei Kang1, Zhe Wang1,2, Guoquan Li1, Shengjun Wang1, Daliang Liu1, Mingru Zhang1, Mingxuan Zhao1, Weidong Yang3, Jing Wang4. 1. Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road, Xi'an, People's Republic of China. 2. Department of Pathology, Xijing Hospital, Fourth Military Medical University, No. 127 West Changle Road, Xi'an, People's Republic of China. 3. Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road, Xi'an, People's Republic of China. yangwd1971@163.com. 4. Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road, Xi'an, People's Republic of China. wangjing@fmmu.edu.cn.
Abstract
PURPOSE: Integrin αvβ3 is the therapeutic target of the anti-angiogenic drug cilengitide. The objective of this study was to compare αvβ3 levels in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients, by using the positron emission tomography (PET) tracer 68Ga-labeled dimerized-RGD (68Ga-RGD2). METHODS: Thirty-one patients with pathologically confirmed lung cancer were enrolled (21 were NSCLC and 10 were SCLC). PET/CT images were acquired using 68Ga-RGD2.18F-FDG PET/CT images were also acquired on the consecutive day as reference. The standard uptake values (SUV) and the tumor/nontarget (T/NT) values were quantitatively compared. Expression of the angiogenesis marker αvβ3 in NSCLC and SCLC lesions was analyzed by immunohistochemistry. RESULTS: The 18F-FDG SUVmax and the SUVmean were not significantly different between NSCLC and SCLC patients. The 68Ga-RGD2 uptake of SCLC patients was at background levels in both SUV and T/NT measurements and was significantly lower than that of NSCLC patients. The range value of 68Ga-RGD2 SUVmean was 4.5 in the NSCLC group and 2.2 in the SCLC group, while the variation coefficient was 36.2% and 39.3% in NSCLC and SCLC primary lesions, respectively. Heterogeneity between primary lesions and putative distant metastases was also observed in some NSCLC cases. Immunostaining showed that αvβ3 integrin was expressed in the cells and neovasculature of NSCLC lesions, while SCLC samples had negative expression. CONCLUSIONS: The uptake of 68Ga-RGD2 in SCLC patients is significantly lower than that in NSCLC patients, indicating a lower αvβ3 target level for cilengitide in SCLC. Apparent intra-tumor heterogeneities of αvβ3 also exist in both NSCLC and SCLC. Such inter- and intra-heterogeneity of αvβ3 may potentially improve current applications of αvβ3-targeted therapy and diagnostic imaging in lung cancer.
PURPOSE: Integrin αvβ3 is the therapeutic target of the anti-angiogenic drug cilengitide. The objective of this study was to compare αvβ3 levels in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients, by using the positron emission tomography (PET) tracer 68Ga-labeled dimerized-RGD (68Ga-RGD2). METHODS: Thirty-one patients with pathologically confirmed lung cancer were enrolled (21 were NSCLC and 10 were SCLC). PET/CT images were acquired using 68Ga-RGD2.18F-FDG PET/CT images were also acquired on the consecutive day as reference. The standard uptake values (SUV) and the tumor/nontarget (T/NT) values were quantitatively compared. Expression of the angiogenesis marker αvβ3 in NSCLC and SCLC lesions was analyzed by immunohistochemistry. RESULTS: The 18F-FDG SUVmax and the SUVmean were not significantly different between NSCLC and SCLCpatients. The 68Ga-RGD2 uptake of SCLCpatients was at background levels in both SUV and T/NT measurements and was significantly lower than that of NSCLCpatients. The range value of 68Ga-RGD2 SUVmean was 4.5 in the NSCLC group and 2.2 in the SCLC group, while the variation coefficient was 36.2% and 39.3% in NSCLC and SCLC primary lesions, respectively. Heterogeneity between primary lesions and putative distant metastases was also observed in some NSCLC cases. Immunostaining showed that αvβ3 integrin was expressed in the cells and neovasculature of NSCLC lesions, while SCLC samples had negative expression. CONCLUSIONS: The uptake of 68Ga-RGD2 in SCLCpatients is significantly lower than that in NSCLCpatients, indicating a lower αvβ3 target level for cilengitide in SCLC. Apparent intra-tumor heterogeneities of αvβ3 also exist in both NSCLC and SCLC. Such inter- and intra-heterogeneity of αvβ3 may potentially improve current applications of αvβ3-targeted therapy and diagnostic imaging in lung cancer.
Entities:
Keywords:
68Ga-labeled dimerized-RGD; Cilengitide; Integrin αvβ3; Non-small cell lung cancer; Small cell lung cancer
Authors: David A Reardon; Karen L Fink; Tom Mikkelsen; Timothy F Cloughesy; Alison O'Neill; Scott Plotkin; Michael Glantz; Paula Ravin; Jeffrey J Raizer; Keith M Rich; David Schiff; William R Shapiro; Susan Burdette-Radoux; Edward J Dropcho; Sabine M Wittemer; Johannes Nippgen; Martin Picard; L Burt Nabors Journal: J Clin Oncol Date: 2008-11-03 Impact factor: 44.544
Authors: Roger Stupp; Monika E Hegi; Thierry Gorlia; Sara C Erridge; James Perry; Yong-Kil Hong; Kenneth D Aldape; Benoit Lhermitte; Torsten Pietsch; Danica Grujicic; Joachim Peter Steinbach; Wolfgang Wick; Rafał Tarnawski; Do-Hyun Nam; Peter Hau; Astrid Weyerbrock; Martin J B Taphoorn; Chiung-Chyi Shen; Nalini Rao; László Thurzo; Ulrich Herrlinger; Tejpal Gupta; Rolf-Dieter Kortmann; Krystyna Adamska; Catherine McBain; Alba A Brandes; Joerg Christian Tonn; Oliver Schnell; Thomas Wiegel; Chae-Yong Kim; Louis Burt Nabors; David A Reardon; Martin J van den Bent; Christine Hicking; Andriy Markivskyy; Martin Picard; Michael Weller Journal: Lancet Oncol Date: 2014-08-19 Impact factor: 41.316
Authors: Roland Haubner; Wolfgang A Weber; Ambros J Beer; Eugenija Vabuliene; Daniel Reim; Mario Sarbia; Karl-Friedrich Becker; Michael Goebel; Rüdiger Hein; Hans-Jürgen Wester; Horst Kessler; Markus Schwaiger Journal: PLoS Med Date: 2005-03-29 Impact factor: 11.069
Authors: Babs G Sibinga Mulder; Henricus Jm Handgraaf; Danielle J Vugts; Claudia Sewing; Albert D Windhorst; Marieke Stammes; Lioe-Fee de Geus-Oei; Mark W Bordo; J Sven D Mieog; Cornelis Jh van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Am J Nucl Med Mol Imaging Date: 2018-10-20
Authors: Andreas Clemmensen; Adam E Hansen; Pernille Holst; Christina Schøier; Sissel Bisgaard; Helle H Johannesen; Jan Henrik Ardenkjær-Larsen; Annemarie T Kristensen; Andreas Kjaer Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-03 Impact factor: 9.236